Hormonal
GLP-1 receptor agonists (GLP-1RAs) do not increase the risk of adverse events compared to non-GLP-1RA antiobesity medications in patients who have undergone bariatric surgery.
If you have had bariatric surgery and are considering GLP-1 medications (like semaglutide or liraglutide) for weight regain, current data suggests they are not more likely to cause adverse events than older weight loss medications. However, the study notes that starting these medications more than 12 months after surgery is associated with a significantly lower risk of adverse events compared to starting them within the first year.
Our results showed that GLP-1RA AOMs were not associated with an increased risk of AEs compared to non-GLP-1RA AOMs in patients who had previously undergone bariatric surgery.
Why this rating
Retrospective cohort study with large sample size (n=599) but potential for confounding and lack of dosing/compliance data.
Source
Adverse event comparison between glucagon‐like peptide‐1 receptor agonists and other antiobesity medications following bariatric surgery
Jason M. Samuels et al. · Diabetes Obesity and Metabolism · 2024
DOI 10.1111/dom.15737
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →